Phase II trial of eribulin mesylate as a first- or second-line treatment for locally advanced or metastatic breast cancer: a multicenter, single-arm trial

Table 2 Efficacy outcomes

	No. of patients	%	95%CI
All assessable patients	32
CR	3	9.4
PR	11	34.4
SD	11	34.4
PD	4	12.5
NE	3	9.4
Overall response (CR + PR)	14	43.8	(26.5–61.0)
Clinical benefit rate (CR + PR + SD≧6 months)	18	56.3	(39.0–73.5)
Tumor control rate (CR + PR + SD)	25	78.1	(63.8–92.5)

ISSN: 1471-2407